158 related articles for article (PubMed ID: 22634535)
21. [Social gradient of PSA screening? 8 years follow up from the cancer registry of the tumor center in Regensburg].
Klotz T; Mathers MJ; Gerken M; Klinkhammer-Schalke M; Hofstädter F
Urologe A; 2010 Dec; 49(12):1503-7. PubMed ID: 20945060
[TBL] [Abstract][Full Text] [Related]
22. Geospatial and temporal variation of prostate cancer incidence.
Wah W; Ahern S; Evans S; Millar J; Evans M; Earnest A
Public Health; 2021 Jan; 190():7-15. PubMed ID: 33321358
[TBL] [Abstract][Full Text] [Related]
23. Significantly reduced incidence and improved survival from prostate cancer over 25 years.
Serdà-Ferrer BC; Sanvisens A; Fuentes-Raspall R; Puigdemont M; Farré X; Vidal-Vila A; Rispau-Pagès M; Baltasar-Bagué A; Marcos-Gragera R
BMC Public Health; 2023 Dec; 23(1):2552. PubMed ID: 38129873
[TBL] [Abstract][Full Text] [Related]
24. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends.
Etzioni R; Penson DF; Legler JM; di Tommaso D; Boer R; Gann PH; Feuer EJ
J Natl Cancer Inst; 2002 Jul; 94(13):981-90. PubMed ID: 12096083
[TBL] [Abstract][Full Text] [Related]
25. The impact of prostate-specific antigen level at diagnosis on the relative survival of 28,531 men with localized carcinoma of the prostate.
Sandblom G; Ladjevardi S; Garmo H; Varenhorst E
Cancer; 2008 Feb; 112(4):813-9. PubMed ID: 18098207
[TBL] [Abstract][Full Text] [Related]
26. Italian cancer figures--Report 2015: The burden of rare cancers in Italy.
; Busco S; Buzzoni C; Mallone S; Trama A; Castaing M; Bella F; Amodio R; Bizzoco S; Cassetti T; Cirilli C; Cusimano R; De Angelis R; Fusco M; Gatta G; Gennaro V; Giacomin A; Giorgi Rossi P; Mangone L; Mannino S; Rossi S; Pierannunzio D; Tavilla A; Tognazzo S; Tumino R; Vicentini M; Vitale MF; Crocetti E; Dal Maso L
Epidemiol Prev; 2016; 40(1 Suppl 2):1-120. PubMed ID: 26951748
[TBL] [Abstract][Full Text] [Related]
27. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up.
Andriole GL; Crawford ED; Grubb RL; Buys SS; Chia D; Church TR; Fouad MN; Isaacs C; Kvale PA; Reding DJ; Weissfeld JL; Yokochi LA; O'Brien B; Ragard LR; Clapp JD; Rathmell JM; Riley TL; Hsing AW; Izmirlian G; Pinsky PF; Kramer BS; Miller AB; Gohagan JK; Prorok PC;
J Natl Cancer Inst; 2012 Jan; 104(2):125-32. PubMed ID: 22228146
[TBL] [Abstract][Full Text] [Related]
28. Prostate cancer mortality in relation to screening by prostate-specific antigen testing and digital rectal examination: a population-based study in middle-aged men.
Agalliu I; Weiss NS; Lin DW; Stanford JL
Cancer Causes Control; 2007 Nov; 18(9):931-7. PubMed ID: 17641982
[TBL] [Abstract][Full Text] [Related]
29. Estimation of time trends of incidence of prostate cancer--an Indian scenario.
Lalitha K; Suman G; Pruthvish S; Mathew A; Murthy NS
Asian Pac J Cancer Prev; 2012; 13(12):6245-50. PubMed ID: 23464439
[TBL] [Abstract][Full Text] [Related]
30. The Long-term Disease-specific Mortality of Low-risk Localized Prostate Cancer: A Prospective Population-based Register Study Over Two Decades.
Klaff R; Rosell J; Varenhorst E; Sandblom G
Urology; 2016 May; 91():77-82. PubMed ID: 26879734
[TBL] [Abstract][Full Text] [Related]
31. Prostate cancer and prostate-specific antigen (PSA) screening in Austria.
Vutuc C; Schernhammer ES; Haidinger G; Waldhör T
Wien Klin Wochenschr; 2005 Jul; 117(13-14):457-61. PubMed ID: 16091872
[TBL] [Abstract][Full Text] [Related]
32. Cohort profile: the MCC-Spain follow-up on colorectal, breast and prostate cancers: study design and initial results.
Alonso-Molero J; Molina AJ; Jiménez-Moleón JJ; Pérez-Gómez B; Martin V; Moreno V; Amiano P; Ardanaz E; de Sanjose S; Salcedo I; Fernandez-Tardon G; Alguacil J; Salas D; Marcos-Gragera R; Chirlaque MD; Aragonés N; Castaño-Vinyals G; Pollán M; Kogevinas M; Llorca J
BMJ Open; 2019 Nov; 9(11):e031904. PubMed ID: 31753885
[TBL] [Abstract][Full Text] [Related]
33. Differences according to socioeconomic status in the management and mortality in men with high risk prostate cancer.
Berglund A; Garmo H; Robinson D; Tishelman C; Holmberg L; Bratt O; Adolfsson J; Stattin P; Lambe M
Eur J Cancer; 2012 Jan; 48(1):75-84. PubMed ID: 21852113
[TBL] [Abstract][Full Text] [Related]
34. Prostate cancer in Italy before and during the 'PSA era': survival trend and prognostic determinants.
Quaglia A; Vercelli M; Puppo A; Casella C; Artioli E; Crocetti E; Falcini F; Ramazzotti V; Tagliabue G;
Eur J Cancer Prev; 2003 Apr; 12(2):145-52. PubMed ID: 12671538
[TBL] [Abstract][Full Text] [Related]
35. Differences in the epidemic rise and decrease of prostate cancer among geographical areas in Southern Europe. an analysis of differential trends in incidence and mortality in France, Italy and Spain.
Quaglia A; Parodi S; Grosclaude P; Martinez-Garcia C; Coebergh JW; Vercelli M
Eur J Cancer; 2003 Mar; 39(5):654-65. PubMed ID: 12628846
[TBL] [Abstract][Full Text] [Related]
36. Italian cancer figures, report 2013: Multiple tumours.
AIRTUM Working Group
Epidemiol Prev; 2013; 37(4-5 Suppl 1):1-152. PubMed ID: 24259384
[TBL] [Abstract][Full Text] [Related]
37. Time trends for prostate cancer mortality in Brazil and its geographic regions: An age-period-cohort analysis.
Braga SFM; de Souza MC; Cherchiglia ML
Cancer Epidemiol; 2017 Oct; 50(Pt A):53-59. PubMed ID: 28810175
[TBL] [Abstract][Full Text] [Related]
38. Serum concentrations of prostate specific antigen and its complex with alpha 1-antichymotrypsin before diagnosis of prostate cancer.
Stenman UH; Hakama M; Knekt P; Aromaa A; Teppo L; Leinonen J
Lancet; 1994 Dec; 344(8937):1594-8. PubMed ID: 7527116
[TBL] [Abstract][Full Text] [Related]
39. Descriptive epidemiology of primary malignant and non-malignant central nervous tumors in Spain: Results from the Girona Cancer Registry (1994-2013).
Fuentes-Raspall R; Solans M; Roca-Barceló A; Vilardell L; Puigdemont M; Del Barco S; Comas R; García-Velasco A; Astudillo A; Carmona-Garcia MC; Marcos-Gragera R
Cancer Epidemiol; 2017 Oct; 50(Pt A):1-8. PubMed ID: 28738268
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
